Rebecca Fredrich
Family · Warsaw, MONPI 1720490360
Payments from drug & device makers
Across 212 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$524
- Teva Pharmaceuticals USA, Inc.$431
- AbbVie$341
- Biogen$276
- Neurocrine Biosciences, Inc.$212
- Novartis$208
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,86095%
- Education$1605%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 47 | $524 |
| Teva Pharmaceuticals USA, Inc. | 28 | $431 |
| AbbVie | 21 | $341 |
| Biogen | 23 | $276 |
| Neurocrine Biosciences, Inc. | 16 | $212 |
| Novartis | 11 | $208 |
| Sumitomo Pharma America, Inc. | 14 | $151 |
| Argenx US, Inc. | 8 | $126 |
| UCB, Inc. | 7 | $118 |
| Pfizer | 4 | $69 |
| MDD US Operations, LLC | 3 | $67 |
| Averitas Pharma Inc. | 3 | $66 |
| Amgen | 3 | $57 |
| Livanova USA, Inc. | 3 | $48 |
| Lilly USA, LLC | 3 | $48 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Banner Life Sciences, LLC | 2 | $36 |
| Eisai Inc. | 2 | $34 |
| Sanofi | 2 | $33 |
| TG Therapeutics, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| Microtransponder, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
| Medtronic | 1 | $15 |
| GRT US Holding, Inc. | 1 | $8 |
| Corium, LLC | 2 | $5 |
How this compares
$3,020 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $168,849 |
| AustedoDeutetrabenazine | 13 | $139,565 |
| VumerityDiroximel Fumarate | 13 | $124,612 |
| Kesimpta PenOfatumumab | 11 | $111,742 |
| AptiomEslicarbazepine Acetate | 34 | $77,148 |
| UbrelvyUbrogepant | 47 | $72,431 |
| Nurtec OdtRimegepant Sulfate | 41 | $58,412 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $38,286 |
| Emgality PenGalcanezumab-Gnlm | 41 | $30,282 |
| ZavzpretZavegepant Hcl | 22 | $23,333 |
| Lamotrigine | 244 | $10,273 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,892 |
| Levetiracetam | 306 | $6,267 |
| Gabapentin | 336 | $5,424 |
| Memantine Hcl | 300 | $5,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $212 | $168,84920 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $431 | $139,56513 claims |
| BiogenVumerity | $276 | $124,61213 claims |
| PfizerNurtec Odt, Zavzpret, Dilantin | $69 | $84,52075 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $18 | $77,14834 claims |
| AbbVieUbrelvy | $341 | $72,43147 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Warsaw
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.